The Drug Provisions of The Inflation Reduction Act are Far from Harmless

Supporters of the Inflation Reduction Act are applauding its drug pricing measures, claiming they will help average Americans get a handle on rising healthcare expenses. But at what cost in terms of health impact?

Together with my colleagues at the University of Chicago, I have found that the existing evidence implies that lowered R&D incentives resulting from the IRA will reduce lifespans by an amount 30 times higher than COVID mortality effects to date.

This calculation is substantially at odds with other assessments, including a recent and influential one by Avik Roy and Gregg Girvan published in the Washington Post. While I often agree with their work, they have misstated the effects in this case.

The full article can be found in RealClear Health.

© Paragon Health Institute 2022. All Rights Reserved.

Paragon Health Institute (PHI) is a non-partisan, not-for-profit policy research institute. Any views, beliefs, or opinions expressed by PHI’s Public Advisors are those of its Advisors and do not necessarily reflect the official policies or positions of PHI or its employees. Any views, beliefs, or opinions expressed by PHI or its employees belong solely to PHI and do not necessarily reflect those of PHI’s Public Advisors.